Pfizer said children’s doses of its Covid-19 vaccine are safe and nearly 91% effective in preventing infections. Details of the study were released today as U.S. regulators are considering extending the vaccination campaign to children ages 5 to 11. If regulators give the green light, dosing could begin early next month.
Pfizer asks the FDA to vaccinate children aged 5-11
The Food and Drug Administration (Fda) is expected to publish the initial review of the company’s safety and efficacy data later. Next week, FDA advisors will publicly discuss the evidence. If the FDA clears low-dose doses, the Centers for Disease Control and Prevention will issue final recommendations as to who should receive them.
The product, Pfizer summarizes, was administered in safe quantities to a sample of 2,268 children, double those who received a placebo: only three minors in the first group contracted the virus compared to sixteen in the second.
Covid vaccine and myocarditis risk: slightly rises with the second dose but 8 out of 10 cases are mild
at Federico Mereta
Pfizer’s full-dose vials are already licensed for anyone 12 or older, but pediatricians and many parents are eagerly awaiting protection for younger children to stem the increase in Delta variant infections and ensure that the children manage to stay in school.
Covid. Children at school, how to avoid infections
by Valeria Pini
